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Abstract
Background: Hepatitis C virus (HCV) encodes two transmembrane glycoproteins E1 and E2
which form a heterodimer. E1 is believed to mediate fusion while E2 has been shown to bind
cellular receptors. It is clear that HCV uses a multi-receptor complex to gain entry into susceptible
cells, however key elements of this complex remain elusive. In this study, the role of a highly
conserved RGE/RGD motif of HCV E2 glycoprotein in viral entry was examined. The effect of each
substitution mutation in this motif was tested by challenging susceptible cell lines with mutant HCV
E1E2 pseudotyped viruses generated using a lentiviral system (HCVpp). In addition to assaying
infectivity, producer cell expression and HCVpp incorporation of HCV E2 proteins, CD81 binding
profiles, and conformation of mutants were examined.
Results: Based on these characteristics, mutants either displayed wt characteristics (high infectivity
[≥ 90% of wt HCVpp], CD81 binding, E1E2 expression, and incorporation into viral particles and
proper conformation) or very low infectivity (≤ 20% of wt HCVpp). Only amino acid substitutions
of the 3rd position (D or E) resulted in wt characteristics as long as the negative charge was
maintained or a neutral alanine was introduced. A change in charge to a positive lysine, disrupted
HCVpp infectivity at this position.
Conclusion: Although most amino acid substitutions within this conserved motif displayed greatly
reduced HCVpp infectivity, they retained soluble CD81 binding, proper E2 conformation, and
incorporation into HCVpp. Our results suggest that although RGE/D is a well-defined integrin
binding motif, in this case the role of these three hyperconserved amino acids does not appear to
be integrin binding. As the extent of conservation of this region extends well beyond these three
amino acids, we speculate that this region may play an important role in the structure of HCV E2
or in mediating the interaction with other factor(s) during viral entry.
Background
To complete its replication cycle, a virus needs to gain
access to the cell cytoplasm by crossing the plasma mem-
brane of a host cell. For enveloped viruses, such as hepati-
tis C virus (HCV), this entails binding at the cell surface,
followed by endocytosis [1]. Entry of HCV is an intricate
process that is not fully understood. Evidence indicates
that HCV requires multiple receptors to invade host cells
[2-4]. However, the key components that mediate suscep-
tibility to HCV still remain elusive. It is known that the
HCV E1 and E2 glycoproteins mediate the tightly regu-
lated process of cell binding and membrane fusion.
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Several cellular surface molecules have been implicated in
HCV entry, including: CD81 [5-8], scavenger receptor
class B type I (SR-BI) [9-12], the low-density lipoprotein
receptor (LDLR) [13,14], Claudin-1, 6 and 9 [15-17], den-
dritic-cell-specific intercellular adhesion molecule 3-grab-
bing nonintegrin (DC-SIGN) [18-20] and Liver/lymph
node-specific intercellular adhesion molecule-3-grabbing
integrin (L-SIGN) [21,22]. While L-SIGN and DC-SIGN
are not expressed on hepatocytes, it is believed that den-
dritic cells expressing these molecules facilitate persistent
infection by capturing and delivering the virus to the liver.
SR-BI is a multiligand receptor that binds several lipopro-
teins, including HDL, LDL and VLDL. It is primarily
expressed in the liver and facilitates the uptake of lipids
[23,24].
As the HCV E2 glycoprotein is exposed to so much selec-
tive pressure and the high error rate inherent in RNA
viruses [25], regions conserved across genotypes suggest
an important role in virus viability. Sequence alignment
of E2 of several genotypes of HCV revealed a highly con-
served RGE or RGD motif at amino acids 648–650 (Fig.
1), which is also flanked upstream and downstream by a
large stretch of sequence conservation. The presence of
RGD/RGE in HCV E2 led us to speculate that integrins
might be involved in HCV binding to the target cells, as
RGD and RGE have been identified as an integrin binding
motif [26-28].
Integrins belong to a large family of cell adhesion mole-
cules (CAMs) [29,30]. They are responsible for cell and
extracellular matrix interactions as well as cell-cell interac-
tions. Unlike many other cell surface receptors, integrins
bind with very low affinity, however they are present in
much larger numbers than other receptors. The binding of
integrins can be compared to Velcro®, low affinity but
with many interaction sites. Integrins are heterodimeric
receptors made up of an α and β subunit [31,32].
In this study, to define the role of the conserved RGE/RGD
motif of E2 in HCV binding and entry, individual substi-
tutions of these three amino acids were generated via site-
directed mutagenesis. Our results suggest that although
RGE/D motif of HCV E2 is critical for viral entry, integrins
are probably not involved. Based on the size of this con-
served region, we speculate that it is of a structural/func-
tional nature.
Results
Identification of a highly conserved RGE/RGD motif
Sequence alignment of several genotypes of HCV E2
reveals all genotypes contain either a RGE or RGD motif
upstream of the transmembrane domain of E2 (aa 648–
650) (Fig. 1). Furthermore, a large region of sequence con-
servation around RGE/RGD is observed, suggesting a
role(s) of this region in structure or/and function of E2.
Effect of amino acid substitutions on the infectivity of 
hepatitis C virus pseudoparticles
To determine if the conserved RGE/RGD motif of HCV E2
is vital for mediating HCVpp entry, substitutions were
generated within the context of H77 E2. Three types of
substitutions were generated: (1) alanine substitutions,
(2) amino acid changes that maintained charge character-
istics and (3) mutations that changed the charge at that
position. After sequence confirmation of the substitu-
tions, HCVpp infectivity of permissive Huh7 cells was
assessed by infecting cells with HIV pseudotyped with wt
or the RGE/RGD motif substitutions (Fig. 2). Infectivity
was determined as a measure of luciferase activity and
VSVG/HIV and EnvA/HIV were used as positive and nega-
tive controls, respectively.
The two amino acid substitutions generated at the first
position, AGE and KGE, completely abrogated HCVpp
infectivity, reducing luciferase levels down to 3 and 5%
respective of wt. Changing the glycine to an alanine at the
second position also reduced infectivity to 18%. As
expected, changing RGE to RGD had no adverse affect on
the viability of infection and resulted in 94% of wt. Inter-
estingly, substituting the negatively charged aspartic acid
(D) or glutamic acid (E) to a neutral alanine (A) did not
impair infectivity of HCVpp, however a positive lysine (K)
at this position reduced HCVpp to 14% of wt. This sug-
gests that a negative or neutral charge at this position is
critical in maintaining HCV E2 interactions with suscepti-
ble cells.
Expression and incorporation of hepatitis C virus E1E2 
RGE substitutions
To confirm changes made in these amino acids did not
adversely affect expression of the HCV E2 protein, expres-
sion levels in the 293 T producer cell lysates transiently
transfected with HIV-luc backbone and the HCV E1E2
glycoprotein plasmids were examined by Western blot
analysis. Blots were also probed for actin as a protein
loading control. Cell lysates probed with anti-E2 antibody
revealed a band of ~70 kDa for all wt and mutant glyco-
protein transfected cells, corresponding to the size of the
HCV E2 glycoprotein (Fig. 3A). All substitutions exhibited
similar expression levels within producer cell lysate.
To determine if reduced infectivity of HCVpp could be
attributed to less glycoprotein incorporation on the pseu-
doparticle, virions were pelleted through a 20% sucrose
cushion and examined via Western blot for E2 incorpora-
tion. Protein p24 capsid of HIV was used as a loading con-
trol (Fig. 3B). E2 incorporation levels were similar for wt
and for all substitutions generated within the RGE/RGDVirology Journal 2009, 6:12 http://www.virologyj.com/content/6/1/12
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motif of E2. These results suggest that these substitution
mutations of the RGE motif in E2 did not adversely affect
E2 expression or incorporation.
Inhibition of hepatitis C virus pseudoparticle entry using 
integrin ligands
To determine the potential role of integrins in HCV entry,
Huh7 cells were incubated with extracellular matrix pro-
teins before addition of HCVpp. Fibronectin (Fn), which
is known to interact with integrins in an RGD dependent
and independent fashion [33] and BSA were preincubated
with Huh7 cells for 1 h at 4°C and then washed and
infected with HCVpp. Seventy-two h PI luciferase reading
were taken as a measure of entry. HCVpp entry was
reduced to ~65–70% of wt at a Fn concentration of 100
μg/ml (Fig. 4A). BSA had no effect on HCVpp entry.
Conserved RGE or RGD motif of hepatitis C virus E2 Figure 1
Conserved RGE or RGD motif of hepatitis C virus E2. HCV strains from the Los Alamos HCV sequence database were 
aligned. The conserved RGE or RGD motif is boxed in red. Amino acids are numbered relative to the AUG start codon of the 
H77 strain (boxed in black) used in this study.
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1a.JP.HC.         VEHRLDAACNWT RGE RCDLED 
1a._.H77-H21.      VEHRLEAACNWT RGE RCDLED 
1b.JP.HCV-O.       VEHRLDAACNWT RGE RCNVED 
1b.TR.HCV-TR1.     VEHRLSAACNWT RGE RCDLED 
1c.ID.HC-G9.       VEHRLDAACNWT RGE RCDLDD 
2a. JFH-1.    VEHRLTAACNFT RGD RCDLED 
2a.JP.HC-J6.       VEHRLTAACNFT RGD RCNLED 
2a.JP.JCH-6.       VEHRLTAACNFT RGD RCNLED 
2b.JP.HC-J8.       VEHRFSAACNFT RGD RCRLED 
2c._.BEBE1.        IEHRLQAACNFT RGD RCNLED 
2i.VN.D54.        IEHRLQAACNFT RGD RCNLDD 
2k.MD.VAT96.       VEHRLEAACNFT RGD RCNLED 
3a.DE.HCVCENS1.    FEHRFTAACNWT RGE RCNIED 
3a.GB.UKN3A4-30.   FEHRFTAACNWT RGE RCDIED 
3b.JP.HCV-Tr.      HEHRFSAACNWT RGE RCDLED 
3b._.Ch54-1.      FNHRFSAACNWT RGE RCDLED 
3k.ID.JK049.       LEHRFNAACNWT RGE RCNLED 
4a.EG.ED43.        IEHRMQAACNWT RGE VCGLEH 
5a.ZA.SA13.        LEHRLEVACNWT RGE RCDLED 
6a.HK.EUHK2.       TEHRFDVACNWT RGE RCELHD 
6b.TH.TH580.       VEHRFDAACNWT RGD RCDLYD 
6d.VN.VN235.       LEHRFDAACNWT RGE RCELED 
6g.ID.JK046.       SEHRFTAACNWT RGE RCDLAD 
6h.VN.VN004.       VEHRFNAACNWT RGD RCELDD 
6k.CN.KM45.        VEHRFDAACNWT RGE RCELDD 
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Peptides with RGE motif inhibit hepatitis C virus 
pseudoparticle containing RGE motif
As genotype 1a strain H77 contains an RGE sequence, syn-
thetic peptides with or without RGE or RGD sequences
were incubated with Huh7 cells for 1 h at 4°C prior to
HCVpp infection. Four synthetic peptides were used:
GRGDTP, GRGESP and a RGD or RGE peptide followed
by 15 amino acids corresponding to the sequence of the
H77 E2 sequence (RGD-E2 and RGE-E2 respectively). The
short, six amino acid peptide GRGESP inhibited HCVpp
entry approximately 80% at a concentration of 15 mM,
however the RGE-E2 peptide did not inhibit HCVpp (Fig.
4B). This could be due to the larger peptides folding on
themselves, masking the RGE sequence. Inhibition by the
GRGESP peptide suggests a potential RGE-dependent
interaction with the Huh7 cell, therefore blocking HCVpp
with integrin antibodies was pursued.
Alpha integrin antibodies to do not block hepatitis C virus 
pseudoparticle entry
Seven monoclonal antibodies that functionally block the
alpha subunit of integrins were incubated with Huh7 cells
at 4°C for 1 h prior to infection with HCVpp. Antibodies
directed against alpha subunits 1–6 and V were tested at a
concentration of 20 μg/ml (data not shown). None of the
antibodies used had an inhibitory effect on HCVpp infec-
tivity, suggesting these alpha subunits are unlikely
involved in the entry process of HCV.
Characterization of RGE/RGD substitutions in CD81 
binding
To investigate whether amino acid substitutions within
the RGE/RGD domain of E2 reduced HCVpp infectivity
through a disruption of CD81 binding, HCV E2 binding
to soluble CD81 was assayed. Binding of HCV E1E2 pro-
teins to a purified GST tag was used as a control. None of
the amino acid substitutions interfered with CD81 and
HCV E2 glycoprotein binding (Fig. 5). These results indi-
cate that decrease in HCVpp infectivity is not due to a loss
of CD81/E2 interaction.
Conformation of RGE/RGD substitutions
To confirm that loss of HCVpp infectivity was not due to
a more general disruption of E2 structure in this region of
the protein, we performed immunoprecipitation with an
antibody that recognizes a conformational epitope within
the putative CD81 binding regions 2 and 3 [34]. Wt and
the amino acid substitutions as well as HCV E2 R614A,
Amino acid substitutions within the conserved RGE motif of E2 dramatically affect hepatitis C virus pseudoparticle entry Figure 2
Amino acid substitutions within the conserved RGE motif of E2 dramatically affect hepatitis C virus pseu-
doparticle entry. 293 T cells were cotransfected with HIV-luc packaging vector along with HCV E1E2 mutant expression 
plasmids. HCVpp was harvested at 48 h PI and used to infect Huh7 cells. Infectivity was measured 72 h PI using a luciferase 
reporter assay. Numbers shown above the bars are infectivity of each mutant expressed as a percentage of the infectivity 
observed for the wild-type (wt) H77 E1E2. Values shown are the mean and standard error for a minimum of three assays.
 Virology Journal 2009, 6:12 http://www.virologyj.com/content/6/1/12
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which was not detectable in a previous study and serves as
a negative control [35], were analyzed in the immunopre-
cipitation. Except for the R614A negative control, all
amino acid substitutions were captured with the confor-
mational antibody, consistent with proper folding (Fig.
6).
Discussion
In this study, we characterized an RGE/RGD motif at
amino acids 648–650 of HCV E2. As integrins are fre-
quently used as receptors for various viral pathogens, and
many integrins recognize RGD sequences, this highly con-
served RGE or RGD motif in the HCV glycoprotein E2 (see
Expression and incorporation of hepatitis C virus E1E2 glycoproteins in producer cell lysate and HCVpp Figure 3
Expression and incorporation of hepatitis C virus E1E2 glycoproteins in producer cell lysate and HCVpp. (A) 
293 T producer cells were lysed on analyzed by Western blot analysis using anti (α)-E2. Detection of actin was performed as a 
loading control. (B) Incorporation of HCV glycoproteins into HCVpp was determined by pelleting the virus through a 20% 
sucrose cushion followed by Western blot analysis. Detection of p24 capsid protein was performed as a loading control.
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Blocking RGE/RGD sites on Huh7 cells prior to hepatitis C virus pseudoparticle challenge Figure 4
Blocking RGE/RGD sites on Huh7 cells prior to hepatitis C virus pseudoparticle challenge. (A) Huh7 cells were 
incubated at 4°C for 1 h with ECM proteins then washed and infected with HCVpp. (B) Inhibition of HCVpp infectivity by pep-
tides GRGDTP, GRGESP, RGD-E2 or RGE-E2 was assessed by incubating Huh7 cells with increasing amounts of peptide at 
4°C for 1 h, washing and infecting with HCVpp. Infecitivity for both was determined 72 h PI using a luciferase reporter assay.
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Fig. 1), led us to hypothesize that integrins might play a
role in HCV binding and entry. While this three amino
acid motif is suggestive of an integrin binding ligand, our
data does not support this hypothesis. Rather, the large
size of this conserved region is more likely indicative of a
structural or other functional role for this region of the E2
glycoprotein.
Of the six amino acid substitutions introduced in this
motif, only substitutions of the last position (aa 650)
maintained infectivity when replaced with either an
amino acid of the same, negative charge (substituting a
glutamic acid with an aspartic acid) or with a neutral
alanine. The E2 gene used in this study, derived from an
H77 strain, contains an RGE at this position. Changing
the glutamic acid to an aspartic acid, which is the other
variation of this conserved motif, maintains infectivity
levels 94% of RGE. A change in charge at this position to
a positive amino acid (lysine) however, impaired infectiv-
ity significantly; dropping infection levels to only 14% of
wt (see Fig. 2). Changes in the first two positions of this
motif reduced HCVpp entry to 3–18%. Producer cell
expression and viral particle incorporation of all of these
substitutions were comparable to wt and could not
account for the reduced HCVpp infectivity (see Fig. 3).
Mutational analysis of this highly conserved, three amino
acid motif underlines its importance in maintaining
HCVpp infectivity.
Receptor binding sites of E2 are not fully understood;
therefore we sought to determine whether or not this con-
served region is involved in binding to CD81. We assayed
the soluble-CD81 binding properties of RGE/D amino
acid substitutions. Mutant E2 protein was expressed in
293 T cells and then assayed for its binding of soluble
CD81 bound to a GST tag. A GST protein alone was uti-
lized as a negative control. All mutants bound CD81 at wt
level, suggesting that whatever role this region plays in the
HCV replication cycle, it does not appear to relate to
CD81 binding (see Fig. 5). Based on the conformational
AR3A antibody analysis (see Fig. 6) and soluble CD81
binding (see Fig. 5), we can conclude that the CD81 bind-
ing epitopes are intact.
Binding of hepatitis C virus E2 glycoproteins containing RGE substitutions to soluble CD81 Figure 5
Binding of hepatitis C virus E2 glycoproteins containing RGE substitutions to soluble CD81. 293 T cells trans-
fected with HCV E1E2 wt of mutant expression vectors were lysed 24 h post-transfection. Cleared cell lysate was incubated 
with soluble CD81-GST fusion protein. Binding to CD81 was determined by Western blot analysis of E2 and the GST tag. As a 
negative control, GST protein without soluble CD81 was incubated with HCV wt.
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The conserved RGE/D initially led us to speculate that
integrins were involved in mediating viral entry of HCV.
Integrins have been shown to mediate binding of several
viruses, including adenovirus, echovirus and hantavirus
[36]. There are 16 α subunits and 8 β subunits that can
interact in numerous ways to generate receptors of differ-
ing ligand specificity. Approximately 24 different het-
erodimers of αβ subunits have been identified, suggesting
not all subunits are capable of interacting with one
another [37]. We preincubated Huh7 cells with 1–6 and V
alpha integrin blocking antibodies prior to HCVpp chal-
lenge to asses if infectivity was impaired. The inability of
these blocking antibodies to prevent HCVpp infectivity
(data not shown) suggests that at least these alpha subu-
nits, are not involved in HCV entry. This conclusion is
consistent with the other results in this study, in particular
the mutational analysis that demonstrates that RGA main-
tains HCVpp entry.
Peptides containing either an RGD or RGE motif were pre-
incubated with Huh7 cells to determine if masking a
potential ligand site on the cell surface could impact
HCVpp infectivity. Of the four peptides generated, the
short, six amino acid peptide GRGESP, reduced HCVpp
infectivity by approximately 80% at 15 mM (see Fig. 4B).
If integrins were directly involved, we would expect to see
the short RGD containing peptide having the same inhib-
itory effect on HCVpp entry, however it did not impair
HCVpp entry. The other RGE containing peptide, RGE-E2,
which is followed by 15 amino acids corresponding to the
HCV E2 H77 strain, did not affect HCVpp entry. This
could be due to the peptide folding on itself and masking
the RGE sequence. Furthermore, addition of fibronectin
prior to HCVpp challenge did not have a significant effect
on inhibiting HCVpp entry (see Fig. 4A) suggesting that
the function of this region is not RGE/D dependent bind-
ing to integrins.
As sequence alignment demonstrates a much larger span
of conservation than simply these three residues (see Fig.
1), we suspect this entire stretch of conserved amino acids
is critical to HCV infection. It is possible that this con-
served region, including the RGE/RGD motif of E2, is crit-
ical for the proper folding and structure of E2. Just
downstream of this three amino acid motif is the trans-
membrane domain, which has been well defined in its
involvement in entry [38-41]. Further investigation is
needed to dissect the exact role of this highly conserved
region of E2 in HCV entry, however this work clearly dem-
onstrates it plays a key role in the HCV replication cycle.
Methods
Cell lines and antibodies
293 T human embryonic kidney cells were maintained in
Dulbecco's modified Eagle's media (DMEM) supple-
mented with 10% fetal calf serum with penicillin, strepto-
mycin. Huh7 and Hep3B cells were maintained in DMEM
supplemented with 10% fetal calf serum, penicillin, strep-
tomycin and supplemented with 5 ml Hepes (1 M)
(Gibco), and Nonessential amino acids (NEAA) (Gibco).
Conformation of HCV E2 glycoprotein substitutions within conserved RGE/RGD motif Figure 6
Conformation of HCV E2 glycoprotein substitutions within conserved RGE/RGD motif. 293 T cells transfected 
with HCV E1E2 wt or RGE/RGD mutant expression vectors were lysed 24 h post-transfection. Cleared cell lysate was incu-
bated with AR3A (C1) conformational antibody to assess conformation of mutations. Immunoprecipitated proteins were 
detected by subsequent Western Blot analysis of E2. HCV E2 R614A was used as a negative control.
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The goat polyclonal antibody against hepatitis C virus
(HCV) E2 and the monoclonal mouse antibody for E1
glycoproteins (GP) (genotype 1a) were obtained through
ViroStat. The mouse anti-HIV p24 monoclonal antibody
was obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program. Polyclonal rab-
bit glutathione-S-transferase (GST) antibody was
obtained from NeoMarkers. The conformational anti-E2
AR3A antibody was provided by Dennis Burton, PhD
from The Scripps Research Institute.
Mutagenesis of the HCV E2 glycoprotein gene
The cDNA clone containing E1E2 from genotype 1a strain
H77 in pCB6, was kindly provided by Charles Rice, PhD
(Rockefeller University). All alanine substitution muta-
tions of the HCV E2 glycoprotein were generated by site-
directed mutagenesis with the Stratagene Quick-Change
mutagenesis kit according to the supplier's protocols. All
mutations were confirmed by DNA sequencing.
Pseudotyping
Pseudotyped viruses were produced by cotransfecting
DNA encoding wild-type (wt) or mutant glycoproteins
with the Env-deficient HIV vector carrying a luciferase
reporter gene (pNL4-3-Luc-R--E-) into 293 T producer
cells. One microgram of the wt or mutant glycoprotein
expression plasmid and 3 μg of pNL4-3-Luc-R--E- were
used to transfect 293 T cells (90% confluent) in 6-well
plates with polyethylenimine (PEI). The DNA cocktail was
added to 200 μl Opti-MEM (Gibco) media and PEI was
added at 2× the volume of DNA. The mixture was incu-
bated at room temperature for 15 min. 293 T producer
cells were rinsed with PBS (no Ca++/no Mg++). Eight hun-
dred microliters of Opti-MEM (Gibco) was added to each
well and the PEI/DNA mixture was added. After 5–6 h
incubation at 37°C, the DNA cocktail was aspirated off
and 3 ml cell culture media was added per well. A mini-
mum of two wells per mutant were done at each time, for
a total of 6 ml. The supernatants containing the pseudo-
typed viruses were collected 48 h post-transfection (PT)
and filtered through a 0.45 μm-pore-size filter (Nalgene).
Pseudotyped virus infectivity assay
Huh7 cells were seeded in 12-well plates at a density of 8
× 104 per well one day prior to infection. Cells were incu-
bated with 500 μl of pseudotyped virus for 6 h, then virus
was removed and cell growth media was added. The cells
were lysed in 200 μl of cell culture lysis reagent (Promega)
at 72 h post-infection (PI). The luciferase activity was
measured with a luciferase assay kit (Promega) and a FB12
luminometer (Berthold detection system) according to
supplier's protocol. Each sample was done in duplicate
and experiments were repeated at least three times.
Western blot analysis
To determine HCV E1E2 expression and incorporation,
293 T producer cells transfected with HCV E1E2/HIV plas-
mids as described above, were lysed in 0.5 ml of 1% Tri-
ton X-100 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 5 mM EDTA) and protease inhibitor cocktail (10
μg/ml leupeptin and pepstatin, 5 μg/ml aprotinin and 2
mM phenylmethylsulfonyl fluoride) after harvesting virus
and rinsing cells with PBS (no Ca++/no Mg++). The protein
samples were spun down at 14 k for 10 min to clear cellu-
lar debris and transferred to fresh eppendorf tubes. SDS-
PAGE loading dye was added to the protein samples,
which were subsequently boiled for 5 min at 95°C, fol-
lowed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to a polyvinyl
difluoride membrane (PVDF). Membranes were then
probed for HCV glycoproteins E1 and E2 and actin, p24 or
GST using peroxidase-conjugated secondary antibody and
chemiluminescence reagent according to the supplier's
protocol (SuperSignal West pico chemiluminescent sub-
strate, Pierce). To determine incorporation of E1 and E2
into the pseudotyped viruses, 4 ml of pseudotyped virus
was layered onto a 1 ml cushion of 20% sucrose in PBS
and centrifuged at 55,000 rpm for 45 min in a SW55Ti
rotor (Beckman Coulter) at 16°C. The pelleted pseudovir-
ions were lysed in 50 μl of 1% Triton X-100 lysis buffer
and subjected to SDS-PAGE and Western blot analysis.
Bovine serum albumin and fibronectin blocking assay
Huh7 cells were seeded in 12-well plates at a density of 8
× 104 per well one day prior to infection. Growth media
was aspirated off and Fibronectin (GibcoBRL) or Bovine
Serum Albumin (BSA) (Fisher) was added in DMEM to
cells. Cells were incubated at 4°C for 1 h. Unbound BSA
or Fibronectin was rinsed off with cold DMEM. Cells were
incubated with 500 μl of pseudotyped virus for 6 h, then
virus was removed and cell growth media was added. The
cells were lysed in 200 μl of cell culture lysis reagent
(Promega) at 72 h post-infection (PI). The luciferase activ-
ity was measured with a luciferase assay kit (Promega) and
a FB12 luminometer (Berthold detection system) accord-
ing to supplier's protocol. Each sample was done in dupli-
cate and repeated twice.
Custom peptide blocking assay
Custom peptides generated were as follows: GRGDTP,
GRDESP, RGDRCDLEDRDRSELSPL (RGD-E2) and
RGERCDLEDRDRSELSPL (RGE-E2). Huh7 cells were
seeded in 12-well plates at a density of 8 × 104 per well one
day prior to infection. Growth media was aspirated off
and peptides were added in DMEM to cells. Cells were
incubated with peptides at 4°C for 1 h. Unbound pep-
tides were rinsed off with cold DMEM. Cells were incu-
bated with 500 μl of pseudotyped virus for 6 h, then virus
was removed and cell growth media was added. The cellsVirology Journal 2009, 6:12 http://www.virologyj.com/content/6/1/12
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were lysed in 200 μl of cell culture lysis reagent (Promega)
at 72 h post-infection (PI). The luciferase activity was
measured with a luciferase assay kit (Promega) and a FB12
luminometer (Berthold detection system) according to
supplier's protocol. Each sample was done in duplicate
and repeated twice.
Alpha integrin blocking assay
Alpha integrin blocking antibody kit was purchased
through Millipore. This kit contained blocking antibodies
for alpha subunits 1–6 and V. Huh7 cells were seeded in
12-well plates at a density of 8 × 104 per well one day prior
to infection. Growth media was aspirated off and antibod-
ies were added to cells along with HCVpp at a final con-
centration of 20 μg/ml. Cells were incubated with
blocking antibodies and HCVpp at 37°C for 3 1/2 h. The
virus and antibody cocktail was then removed and cell
growth media was added. The cells were lysed in 200 μl of
cell culture lysis reagent (Promega) at 72 h post-infection
(PI). The luciferase activity was measured with a luciferase
assay kit (Promega) and a FB12 luminometer (Berthold
detection system) according to supplier's protocol. Each
sample was done in triplicate.
CD81 binding assay
The CD81 clone used was kindly provided by Shoshana
Levy, PhD (Stanford University). A glutathione S-trans-
ferase (GST) fusion protein containing the large extracel-
lular loop (LEL) of human CD81 was generated as
previously described [5]. 293 T producer cells were trans-
fected with 1 μg HCV E1E2 DNA using PEI. After 48 h cells
were lysed in 0.5% Triton X-100 lysis buffer with protease
inhibitor on ice for 30 min. Cell lysates were clarified by
centrifuging at 20,000 × g for 30 min at 4°C. Two-hun-
dred microliters of clarified lysates from these cells were
incubated with 5 μg of CD81-GST fusion protein or GST
protein alone with gentle rocking at 4°C for 16 h. Fifty
microliters of Glutathione Sepharose 4B (GSH) beads (GE
Healthcare) rinsed three times with PBS (140 mM NaCl,
27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) were
added and incubated at 4°C for 1 h. The slurry was spun
down for 1 min at 14, 000 rpm and GSH beads were
rinsed two times with 0.5% Triton X-100 lysis buffer. SDS-
PAGE loading dye was added to the beads and samples
were boiled at 95°C for 5 min. Slurry was spun down
again and supernatant was collected for SDS-PAGE and
Western blot analysis.
E2 conformational antibody immunoprecipitation
293 T producer cells were transfected with 1 μg wt or a
selection of CD81 binding deficient or binding competent
mutant HCV E1E2 DNA constructs using PEI. After 48 h
cells were lysed in 0.5% Triton X-100 lysis buffer with pro-
tease inhibitor on ice for 30 min. Cell lysates were clari-
fied by centrifuging at 20,000 × g for 30 min at 4°C. Four-
hundred microliters of clarified lysates from these cells
were incubated with 1 μg of AR3A conformational anti-
body [34] with gentle rocking at 4°C for 16 h. Immobi-
lized protein A (Pierce) beads were rinsed three times with
PBS (140 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4). Fifty microliters of rinsed polyA beads
were then added to the cell lysate/antibody cocktail and
incubated with gentle rocking at 4°C for 2 h. Beads were
washed three times with 100 μl 0.5% Triton lysis buffer.
SDS-PAGE loading dye was added to the beads and sam-
ples were boiled at 95°C for 5 min. Slurry was spun down
and supernatant was collected for SDS-PAGE separation
and Western blot analysis with a polyclonal anti E2 anti-
body (Virostat).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KBR participated in the design of the study, performed the
experiments and drafted the manuscript. LR designed the
study and participated in drafting the manuscript.
Acknowledgements
We thank Dr. Susan Uprichard for her help and useful discussions. The lab-
oratory research was supported by National Institutes of Health grants AI 
048056 and AI 059570.
References
1. Lindenbach BD, Rice CM: Flaviviridae: The viruses and their
replication.  In Field's Virology Volume 2. 4th edition. Edited by: Knipe
DM, Howley PM. Philadelphia: Pippincott Williams & Wilkins;
2001:991-1041. 
2. Cocquerel L, Voisset C, Dubuisson J: Hepatitis C virus entry:
potential receptors and their biological functions.  J Gen Virol
2006, 87:1075-84.
3. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S,
Scarselli E, Cortese R, Nicosia A, Cosset FL: Cell entry of hepatitis
C virus requires a set of co-receptors that include the CD81
tetraspanin and the SR-B1 scavenger receptor.  J Biol Chem
2003, 278:41624-30.
4. Diedrich G: How does hepatitis C virus enter cells?  Febs J 2006,
273:3871-85.
5. Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M,
Ceccacci A, Vitelli A, Levy S, Nicosia A, Traboni C, McKeating J,
Scarselli E: Binding of hepatitis C virus E2 glycoprotein to
CD81 does not correlate with species permissiveness to
infection.  J Virol 2000, 74:5933-8.
6. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R,
Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S: Binding of
hepatitis C virus to CD81.  Science 1998, 282:938-41.
7. Flint M, von Hahn T, Zhang J, Farquhar M, Jones CT, Balfe P, Rice CM,
McKeating JA: Diverse CD81 proteins support hepatitis C virus
infection.  J Virol 2006, 80:11331-42.
8. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T:
CD81 is an entry coreceptor for hepatitis C virus.  Proc Natl
Acad Sci USA 2004, 101:7270-4.
9. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G,
Traboni C, Nicosia A, Cortese R, Vitelli A: The human scavenger
receptor class B type I is a novel candidate receptor for the
hepatitis C virus.  Embo J 2002, 21:5017-25.
10. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, Budkowska A:
The interaction of natural hepatitis C virus with human scav-
enger receptor SR-BI/Cla1 is mediated by ApoB-containing
lipoproteins.  Faseb J 2006, 20:735-7.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:12 http://www.virologyj.com/content/6/1/12
Page 11 of 11
(page number not for citation purposes)
11. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-
Dac N: High density lipoproteins facilitate hepatitis C virus
entry through the scavenger receptor class B type I.  J Biol
Chem 2005, 280:7793-9.
12. Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farqu-
har M, Schwarz A, Moreau M, Owen JS, Leroux-Roels G, Balfe P,
MaKeating JA: Scavenger receptor BI and BII expression levels
modulate hepatitis C virus infectivity.  J Virol 2007, 81:3162-9.
13. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S,
Thomssen R: Low density lipoprotein receptor as a candidate
receptor for hepatitis C virus.  J Med Virol 1999, 57:223-9.
14. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C
virus and other flaviviridae viruses enter cells via low density
lipoprotein receptor.  Proc Natl Acad Sci USA 1999, 96:12766-71.
15. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B,
Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM: Claudin-1 is a
hepatitis C virus co-receptor required for a late step in entry.
Nature 2007, 446:801-5.
16. Zheng A, Yuan F, Li Y, Zhu F, Hou P, Li J, Song X, Ding M, Deng H:
Claudin-6 and claudin-9 function as additional coreceptors
for hepatitis C virus.  J Virol 2007, 81:12465-71.
17. Mee CJ, Grove J, Harris HJ, Hu K, Balfe P, McKeating JA: Effect of
cell polarization on hepatitis C virus viral entry.  J Virol 2007.
18. Pohlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-
Piperno A, Doms RW, Rice CM, McKeating JA: Hepatitis C virus
glycoproteins interact with DC-SIGN and DC-SIGNR.  J Virol
2003, 77:4070-80.
19. Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neu-
mann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccala
G, Depla E, Liang TJ, Blum HE, Baumert TF: Uptake and presenta-
tion of hepatitis C virus-like particles by human dendritic
cells.  Blood 2005, 105:3605-14.
20. van Kooyk Y, Geijtenbeek TB: DC-SIGN: escape mechanism for
pathogens.  Nat Rev Immunol 2003, 3:697-709.
21. Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F,
Cosset FL, Altmeyer R: C-type lectins L-SIGN and DC-SIGN
capture and transmit infectious hepatitis C virus pseudotype
particles.  J Biol Chem 2004, 279:32035-45.
22. Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC,
Gardner JP, Dragic T: L-SIGN (CD209L) and DC-SIGN
(CD209) mediate transinfection of liver cells by hepatitis C
virus.  Proc Natl Acad Sci USA 2004, 101:14067-72.
23. Rigotti A, Miettinen HE, Krieger M: The role of the high-density
lipoprotein receptor SR-BI in the lipid metabolism of endo-
crine and other tissues.  Endocr Rev 2003, 24:357-87.
24. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV: Initiation
of hepatitis C virus infection is dependent on cholesterol and
cooperativity between CD81 and scavenger receptor B type
I.  J Virol 2007, 81:374-83.
25. Elena SF, Sanjuan R: Adaptive value of high mutation rates of
RNA viruses: separating causes from consequences.  J Virol
2005, 79:11555-8.
26. Ruoslahti E, Pierschbacher MD: New perspectives in cell adhe-
sion: RGD and integrins.  Science 1987, 238:491-7.
27. Pytela R, Pierschbacher MD, Argraves S, Suzuki S, Ruoslahti E:
Arginine-glycine-aspartic acid adhesion receptors.  Methods
Enzymol 1987, 144:475-89.
28. Pierschbacher MD, Ruoslahti E: Cell attachment activity of
fibronectin can be duplicated by small synthetic fragments of
the molecule.  Nature 1984, 309:30-3.
29. Hynes RO: Integrins: bidirectional, allosteric signaling
machines.  Cell 2002, 110:673-87.
30. Humphries MJ: Integrin structure.  Biochem Soc Trans 2000,
28:311-39.
31. Arnaout MA, Mahalingam B, Xiong JP: Integrin structure, allos-
tery, and bidirectional signaling.  Annu Rev Cell Dev Biol 2005,
21:381-410.
32. Springer TA, Wang JH: The three-dimensional structure of
integrins and their ligands, and conformational regulation of
cell adhesion.  Adv Protein Chem 2004, 68:29-63.
33. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW: Ligand binding to
integrins.  J Biol Chem 2000, 275:21785-8.
34. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gas-
taminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Knete-
man NM, Burton DR: Broadly neutralizing antibodies protect
against hepatitis C virus quasispecies challenge.  Nat Med
2008, 14:25-7.
35. Rothwangl KB, Manicassamy B, Uprichard SL, Rong L: Dissecting
the role of putative CD81 binding regions of E2 in mediating
HCV entry: putative CD81 binding region 1 is not involved in
CD81 binding.  Virol J 2008, 5:46.
36. Stewart PL, Nemerow GR: Cell integrins: commonly used
receptors for diverse viral pathogens.  Trends Microbiol 2007,
15:500-7.
37. Humphries JD, Byron A, Humphries MJ: Integrin ligands at a
glance.  J Cell Sci 2006, 119:3901-3.
38. Ciczora Y, Callens N, Penin F, Pecheur EI, Dubuisson J: Transmem-
brane domains of hepatitis C virus envelope glycoproteins:
residues involved in E1E2 heterodimerization and involve-
ment of these domains in virus entry.  J Virol 2007, 81:2372-81.
39. Ciczora Y, Callens N, Montpellier C, Bartosch B, Cosset FL, Op de
Beeck A, Dubuisson J: Contribution of the charged residues of
hepatitis C virus glycoprotein E2 transmembrane domain to
the functions of the E1E2 heterodimer.  J Gen Virol 2005,
86:2793-8.
40. Cocquerel L, Meunier JC, Pillez A, Wychowski C, Dubuisson J: A
retention signal necessary and sufficient for endoplasmic
reticulum localization maps to the transmembrane domain
of hepatitis C virus glycoprotein E2.  J Virol 1998, 72:2183-91.
41. Lavie M, Goffard A, Dubuisson J: Assembly of a functional HCV
glycoprotein heterodimer.  Curr Issues Mol Biol 2007, 9:71-86.